Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease

Xian-Wen Dong, Qing Zheng, Ming-Ming Zhu, Jing-Lu Tong, Zhi-Hua Ran

Abstract

AIM: To evaluate the relationship between thiopurine S-methyltransferase (TPMT) polymorphisms and thiopurine-induced adverse drug reactions (ADRs) in inflammatory bowel disease (IBD).

METHODS: Eligible articles that compared the frequency of TPMT polymorphisms among thiopurine-tolerant and -intolerant adult IBD patients were included. Statistical analysis was performed with Review Manager 5.0. Sub-analysis/sensitivity analysis was also performed.

RESULTS: Nine studies that investigated a total of 1309 participants met our inclusion criteria. The incidence of TPMT gene mutation was increased 2.93-fold (95% CI: 1.68-5.09, \(P = 0.0001\)) and 5.93-fold (95% CI: 2.96-11.88, \(P = 0.0001\)), respectively, in IBD patients with thiopurine-induced overall ADRs and bone marrow toxicity (BMT), compared with controls. The OR for TPMT gene mutation in IBD patients with thiopurine-induced hepatotoxicity and pancreatitis was 1.51 (95% CI: 0.54-4.19, \(P = 0.43\)) and 1.02 (95% CI: 0.26-3.99, \(P = 0.98\)) vs controls, respectively.

CONCLUSION: This meta-analysis suggests that the TPMT polymorphisms are associated with thiopurine-induced overall ADRs and BMT, but not with hepatotoxicity and pancreatitis.

Key words: Methyltransferases; Inflammatory bowel diseases; Meta-analysis; Adverse drug reactions; Bone marrow toxicity

INTRODUCTION

Inflammatory bowel disease (IBD) is a chronic, relapsing and remitting disease of the gastrointestinal tract. The major types of IBD are Crohn’s disease (CD) and ulcerative colitis (UC). The thiopurine drugs azathioprine (AZA) and 6-mercaptopurine (6-MP) are widely used to treat patients with active, steroid-refractory, and steroid-dependent IBD, and have been proven to be effective for inducing and maintaining remission of CD[12]. Unfortu-
nately, the dose of thiopurine often has to be reduced or the therapy has to be discontinued in 9%-28% of patients because of adverse drug reactions (ADRs). Gastrointestinal disturbances, bone marrow toxicity (BMT), hepatotoxicity and pancreatitis are among the most frequent reasons to prevent their use in some patients.

Blood tests have been performed regularly to monitor the blood count and liver function to detect BMT and hepatotoxicity at an early enough stage to discontinue therapy and avoid life-threatening toxicity. However, the ADRs might develop suddenly and unpredictably during the interval between two tests. Thus, screening the patients before thiopurine treatment for genetic susceptibilities to predict the risk of toxicity has aroused considerable interest in several clinical centers.

Thiopurine S-methyltransferase (TPMT) is a very important enzyme for the metabolism of thiopurine compounds. Lack of its activity has been associated with the incidence of BMT induced by thiopurine therapy. Genetic polymorphisms that account for reduced (heterozygote) or absent (homozygote) TPMT activity have been confirmed. About 10% of the patients have intermediate activity due to heterozygosity of the TPMT, and 1 in 300 patients inherit TPMT deficiency as an homozygote. TPMT*1 is the wild type, TPMT*3A is the most prevalent mutant allele (85%) in Caucasians and TPMT*3C is the most common reported mutant alleles in African and South-East Asian populations. Although several studies have shown that low TPMT activity is associated with BMT, the efficacy of the strategy of screening the TPMT gene mutation in all patients prior to initiating treatment with thiopurine drugs has not yet been definitively confirmed.

The aim of this meta-analysis was to evaluate whether there is a relationship between TPMT polymorphisms and incidence of ADRs in IBD patients.

**MATERIALS AND METHODS**

**Search strategy**

The databases PubMed (1966 to July 2009), Embase (1980 to July 2009), Cochrane Controlled Trials Register (Issue 1, 2009), Science Citation Index (1945 to July 2009) and Chinese Biomedical Database (1981 to July 2009) were used for systematic literature searches. We employed both MeSH and free-language terms for “TPMT”, “thiopurine S-methyltransferase” AND “inflammatory bowel disease”, “ulcerative colitis”, OR “Crohn’s disease” combined with each of the following: “thiopurine”, “azathioprine”, “imuran”, “6-mercaptopurine” as search terms. A comprehensive search of reference lists of all review articles and original studies retrieved by this method was performed to identify additional studies. Furthermore, we also searched abstracts of major gastroenterological meetings, such as the Digestive Disease Week of the American Gastroenterological Association, the World Congress of Gastroenterology and British Society of Gastroenterology. Authors of some identified trials were asked whether they knew of additional studies, including unpublished ones.

**Inclusion and exclusion criteria**

The selection criteria were as follows: cross-sectional cohort, prospective cohort and case-control studies were included in the meta-analysis. Studies in abstract form or meeting reports, without publication of the full paper, were also included in the meta-analysis. Only IBD patients aged over 18 years were included.

Studies were included that compared TPMT polymorphism frequencies among thiopurine-tolerant and -intolerant adult IBD patients. Two of the most prevalent mutant types of the TPMT gene were studied, namely, TPMT*3A and TPMT*3C polymorphisms. Studies were included if they provided information on at least one outcome parameter as follows: proper OR of overall ADRs, BMT, hepatotoxicity or pancreatitis.

Furthermore, articles published in English and Chinese were included. Studies in other languages were excluded unless a translation was available.

**Data extraction**

Standardized data abstraction sheets were prepared. Data were extracted for author and year, location of trials, trial design, diseases, number of enrolled subjects, and dose of thiopurine, meanwhile, key outcome data, such as TPMT polymorphisms and thiopurine induced overall ADRs, BMT, hepatotoxicity and pancreatitis were abstracted from the selected studies. All papers were examined independently for eligibility by two reviewers (Dong XW and Zheng Q). Disagreements were resolved by consulting a third reviewer (Ran ZH). When the results of a particular study were reported in more than one publication, only the most recent and complete data were included in the meta-analysis. Finally, the manuscripts were studied for their comparability by Zhu MM and Tong JL.

**Statistical analysis**

Data were entered into the Cochrane Collaboration RevMan 5.0 (Copenhagen, 2008). OR with 95% CI was calculated for the TPMT*3A and TPMT*3C polymorphisms vs overall ADRs, BMT, hepatotoxicity and pancreatitis. Because of too small a number of patients, heterozygous and homozygous patients were combined as “polymorphism-positive”. An OR of <-1 favored the control group, P < 0.05 and 95% CI that did not include the value 1 were considered to be statistically significant. The included studies displayed heterogeneity regarding study design, definition of ADRs, and follow-up periods. Therefore, it would be inappropriate to combine the data for further analysis with the fixed-effects model, whereas the random effects model was used for calculations. Finally, we used funnel plot asymmetry to detect any publication bias in the meta-analysis, and Egger’s regression test to measure funnel plot asymmetry.

**RESULTS**

**Description of the studies**

We reviewed 181 citations and abstracts obtained from our computerized literature searches. Fifty-nine papers
Table 1 Characteristics of excluded studies

| Author       | Location | Study design | Participants | TPMT genotypes was determined | Dose of thiopurine | Reason for exclusion |
|--------------|----------|--------------|--------------|-------------------------------|--------------------|------------------|
| Cao et al[9], 2009 | China    | Cross-sectional | 43 treated IBD patients | TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C | AZA 1.35 mg/kg per day | Incomplete data |
| Takabu et al[5], 2009 | Japan    | Cross-sectional | 147 treated IBD patients | TPMT*2, TPMT*3B, TPMT*3C, TPMT*8 | AZA 25 mg/d or 75 mg/d or 100 mg/d | Incomplete data |
| Uchiyama et al[10], 2009 | Japan    | Cross-sectional | 16 treated IBD patients with ADRs | TPMT*2, *3A, *3B, TPMT*3C, *3D, *4 | AZA < 50 mg/d or 6-MP < 30 mg/d | Incomparable control group |
| Ban et al[11], 2008 | Japan    | Case-control | 70 treated IBD patients | TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C | Not mentioned | No definition of ADRs |
| Geary et al[12], 2003 | New Zealand | Case-control | 56 treated IBD patients with ADRs | TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C | Not mentioned | Pediatric patients included |
| Regueiro et al[13], 2002 | USA      | Cross-sectional | 71 treated CD patients | TPMT*3A, TPMT*3B, TPMT*3C | AZA 2.35 mg/kg per day or 1.28 mg/kg per day | Dose of thiopurine not mentioned |
| Evans et al[14], 2001 | USA      | Cross-sectional | 23 treated patients with ADRs | TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C | AZA 32 mg/m² per week or 175 mg/m² per week or 280 mg/m² per week | Dose of thiopurine not mentioned |
| Naughton et al[15], 1999 | UK       | Cross-sectional | 15 treated IBD patients | TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C | Not mentioned | Non-IBD patients |

Dose of thiopurine: mean or median dose of thiopurine. TPMT: Thiopurine S-methyltransferase; IBD: Inflammatory bowel disease; AZA: Azathioprine; ADRs: Adverse drug reactions; 6-MP: 6-mercaptopurine; CD: Crohn’s disease.

were excluded on the basis of publication type and another 105 were excluded after examining the title and abstract. Among these 17 potentially appropriate studies, we found that all of them had studied the association between TPMT polymorphisms and thiopurine-induced ADRs. Abstracts and full texts of the remaining 17 papers were retrieved for further assessment. Of these potential eligible articles, we excluded another eight[6-13], which are listed in Table 1. Two studies were not able to extract the data from the published results, and we also failed to contact the authors of this manuscript, therefore, these two studies were excluded. Three studies were excluded for not mentioning the prescription dose of thiopurine. One study was excluded as it did not set a control group, such that a proper OR could not be calculated. One study was excluded since it included non-IBD patients. In one study, not all of the patients had determination of TPMT genotype. Finally, nine studies[13,14,19] met the inclusion criteria; all of which were published in the last 7 years. Three were prospective cohort studies, with the remaining six being cross-sectional. The flowchart of reviews showed the detailed process of selection (Figure 1). The characteristics of the nine trials included in the meta-analysis are summarized in Table 2. The outcomes of the meta-analysis are shown in Figure 2.

**OVERALL ADRs**

Six[13,14,17,18,20] of the nine studies reported on the incidence of overall ADRs in 273 IBD patients exposed to thiopurine drugs of 708 IBD patients without ADRs. ADRs included BMT, hepatotoxicity, pancreatitis, gastrointestinal disturbances and adverse reactions during treatment that required reduction of thiopurine dose or discontinuation of therapy. Three[13,15,20] of the studies demonstrated that the AZA/6-MP-induced ADRs were independent of the TPMT polymorphisms; the remaining three showed that TPMT polymorphisms strongly predicted ADRs. The TPMT polymorphisms were significantly associated with ADRs in the overall calculated OR (OR: 2.93, 95% CI: 1.68-5.09, P = 0.0001). When excluding hepatotoxicity and...
Table 2  Characteristics of included studies

| Author                       | Location | Study design   | Participants | TPMT genotypes was determined | Dose of thiopurine            | ADRs and definitions                                                   |
|------------------------------|----------|----------------|--------------|-------------------------------|------------------------------|------------------------------------------------------------------------|
| Ansari et al[4], 2008        | UK       | Prospective cohort | 215 treated IBD patients | TPMT*3A, TPMT*3B, TPMT*3C       | AZA 2 mg/kg per day          | All ADRs                                                              |
|                              |          |                |              |                               |                              | BMT: WBC < 3 × 10^9 or Ne < 1.5 × 10^9 |
|                              |          |                |              |                               |                              | H: ALT > 2 × ULN                                                            |
|                              |          |                |              |                               |                              | P: Amylase, lipase > 4 × ULN and supportive radiological findings |
| Hawwa et al[19], 2008        | UK       | Cross-sectional | 36 treated IBD patients | TPMT*3A, TPMT*3B, TPMT*3C       | AZA 1.49 mg/kg per day       | All ADRs                                                              |
|                              |          |                |              |                               |                              | BMT: WBC < 3.0 × 10^9 or Ne < 1.5 × 10^9 |
|                              |          |                |              |                               |                              | P: No definition                                                             |
| Winter et al[6], 2007        | UK       | Cross-sectional | 130 treated IBD patients | TPMT*3A, TPMT*3A, TPMT*3C, TPMT*3A | AZA 1.6 mg/kg per day       | All ADRs                                                              |
|                              |          |                |              |                               |                              | BMT: WBC < 3 × 10^9 or PLT < 150 × 10^9 |
|                              |          |                |              |                               |                              | H: No definition                                                              |
| Stocco et al[10], 2007       | Italy    | Cross-sectional | 70 treated IBD patients | TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C, TPMT*3C | AZA: 2 mg/kg per day | All ADRs                                                              |
| Palmieri et al[11], 2007     | Italy    | Cross-sectional | 422 treated IBD patients | TPMT*3A, TPMT*3B, TPMT*3C       | AZA 2.25 mg/kg per day or 6-MP 1.25 mg/kg per day | All ADRs                                                              |
| Zelinkova et al[12], 2006    | Netherlands | Cross-sectional | 262 treated IBD patients | TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C, TPMT*3C, TPMT*3C, *3C, *4 | AZA 2.25 mg/kg per day | All ADRs                                                              |
| Hindorf et al[13], 2006      | Sweden   | Prospective cohort | 60 treated IBD patients | TPMT*2, TPMT*3B, TPMT*3B         | 6-MP 0.71 mg/kg per day      | All ADRs                                                              |
| Derijks et al[14], 2004      | Netherlands | Cross-sectional | 30 treated IBD patients | TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C, TPMT*3C, TPMT*3C, *3C, *3D | 6-MP 1.5 mg/kg per day       | All ADRs                                                              |
| Schwab et al[15], 2002       | Germany  | Cross-sectional | 93 treated IBD patients | TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C, TPMT*3C, *3C, *5D | 1.5 mg/kg per day or 1.9 mg/kg per day | All ADRs                                                              |

1The initial dose. White blood cells (WBC), neutrophils (Ne), and platelets (PLT) are expressed per liter; H: Hepatotoxicity; P: Pancreatitis; AP: Abdominal pain; BMT: Bone marrow toxicity; ALT: Alanine transaminase; ULN: Upper limit of normal; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase.

pancreatitis from the overall ADRs group, it still indicated that IBD patients exposed to thiopurine drugs, with ADRs, were more likely to have ‘TPMT polymorphisms than the controls (OR: 4.37, 95% CI: 1.69-11.29, P = 0.002).

**BMT**

All of the nine studies[5,14-20] reported on the incidence of BMT in 1309 IBD patients treated with thiopurine. Twenty-three of 77 IBD patients with BMT and 87 of 1232 IBD patients without BMT had the TPMT gene mutation. Researchers from the United Kingdom[14] defined BMT as a white blood cells count of < 3.5 × 10^9/L or a neutrophil count of < 1.5 × 10^9/L. In the study of Winter et al[14], BMT was defined as a white blood cells count of < 3.0 × 10^9/L. Researchers from Sweden[15] have defined BMT as a white blood cells count of < 3.0 × 10^9/L, a neutrophil count of < 1.5 × 10^9/L, or a platelet count of < 100 × 10^9/L. Hawwa et al[19] have defined BMT as a white blood cells count of < 3.0 × 10^9/L, a neutrophil count of < 1.5 × 10^9/L, or a platelet count of < 150 × 10^9/L. Dutch researchers[10] have defined BMT as a white blood cells count of < 4.0 × 10^9/L or a platelet count of < 100 × 10^9/L. It was defined in the remaining four studies[16,18-20] as a white blood cells count of < 3.0 × 10^9/L or a platelet count of < 100 × 10^9/L. Of these selected studies, five reported that heterozygous TPMT genotype strongly predicted BMT, and the remaining four failed to demonstrate an association between TPMT gene mutation and risk of BMT. The pooled OR demonstrated that TPMT polymorphisms were significantly associated with BMT (OR: 5.93, 95% CI: 2.96-11.88, P < 0.00001).

**Hepatotoxicity**

Six studies[5,14,16-18,20] have reported on the incidence of hepatotoxicity in IBD patients treated with thiopurines. Three[14,17-18] of these have defined hepatotoxicity as alanine transaminase (ALT) levels of at least twice the upper limit of normal (ULN). A German research group[18] defined hepatotoxicity as either ALT levels or aspartate aminotransferase (AST) levels of at least twice the ULN. Stocco et al[19] have defined hepatotoxicity as ALT, AST or alkaline phosphatase (ALP) levels of at least twice the ULN. No definition of hepatotoxicity was provided in the study of Winter et al[14], therefore, this study was excluded in this sub-analysis. Only three of the 37 IBD patients with hepatotoxicity were ‘TPMT heterozygotes/homozygotes, while 82 of 1017 IBD patients without hepatotoxicity were ‘TPMT heterozygotes/homozygotes. All of the remaining five have shown that there was no association between AZA-related hepatotoxicity and TPMT poly-
morphisms. The pooled OR indicated that no significant difference in TPMT polymorphisms was seen between IBD patients with thiopurine-induced hepatotoxicity and controls (OR: 1.51, 95% CI: 0.54-4.19, \(P = 0.43\)).

Pancreatitis

Six studies\(^{[3,5,14,17,18,20]}\) have reported on the incidence of pancreatitis in IBD patients treated with thiopurine and detected TPMT polymorphisms. In the study of Ansari...
et al.\[^{14}\] have defined pancreatitis as either serum amylose or serum lipase of more than two times the ULN, associated with severe abdominal pain. Only one of 34 IBD patients with pancreatitis and 60 of 758 without pancreatitis had the TPMT gene mutation. All of the four studies have demonstrated that there was no association between pancreatitis and TPMT polymorphisms. Pooled data have demonstrated that there was no significant difference in TPMT polymorphisms between IBD patients with thiopurine-induced pancreatitis and controls (OR: 1.02, 95% CI: 0.26-3.99, \( P = 0.98 \)).

**Subgroup analysis**

We performed subgroup analysis in which we excluded the studies with different definitions of BMT to determine the effect on the test of heterogeneity and the overall pooled estimates. Because the results were nearly identical, only results based on the four studies\[^{16-18,20}\] that have defined BMT as a white blood cells count of \(< 3.0 \times 10^9/L\) or a platelet count of \(< 100 \times 10^9/L\) were reported. The pooled OR of the four studies\[^{16-18,20}\] was 5.05 (95% CI: 2.58-9.88, \( P < 0.01 \)). This result still showed a significant difference in TPMT polymorphisms between IBD patients with and without BMT. Similarly, we also performed subgroup analysis in which we individually excluded the studies with different definitions of hepatotoxicity and pancreatitis, to determine the effect on the test of heterogeneity and the overall pooled estimates. Because the results were nearly identical, they were not reported.

**Sensitivity analysis**

Studies that prescribed AZA ≤ 2 mg/kg per day or 6-MP ≤ 1 mg/kg per day. When the studies\[^{15,14,16-18}\] that prescribed AZA > 2 mg/kg per day or 6-MP > 1 mg/kg per day were excluded, results remained consistent with original results. A significant difference in the incidence of TPMT polymorphisms was observed in the overall ADRs group (OR: 7.82, 95% CI: 2.18-28.12, \( P < 0.01 \)) and BMT group (OR: 6.73, 95% CI: 3.52-12.58, \( P < 0.0001 \)) compared with the controls. However, no significant difference was found in the hepatotoxicity group (OR: 1.04, 95% CI: 0.18-5.90, \( P = 0.96 \)) and pancreatitis group (OR: 1.36, 95% CI: 0.28-6.49, \( P = 0.70 \)) compared with the controls.

**Including the excluded studies**

When the excluded studies\[^{9,10,13}\] that provided information on at least one outcome parameter such as proper OR of overall ADRs, BMT, hepatotoxicity or pancreatitis were taken into account, there was still a significant difference in TPMT polymorphisms between IBD patients with or without ADRs. It also showed an increase in the risk of the incidence of TPMT polymorphisms in the overall ADRs group (OR: 2.76, 95% CI: 1.69-4.50, \( P < 0.0001 \)) and BMT group (OR: 6.73, 95% CI: 3.52-12.58, \( P < 0.0001 \)) compared with the controls. No significant difference in the incidence of TPMT polymorphisms was found in the hepatotoxicity group (OR: 1.27, 95% CI: 0.53-3.07, \( P = 0.59 \)) and pancreatitis group (OR: 1.32, 95% CI: 0.46-3.76, \( P = 0.60 \)) compared with the controls.

**Publication bias**

Figure 3 shows a funnel plot of the studies used in this meta-analysis that have reported on ≥ 100 IBD patients treated with thiopurine, and detected TPMT polymorphisms showed that the results were consistent with the overall results and the analysis of the original studies. A significant difference in the incidence of TPMT polymorphisms was observed in the overall ADRs group (OR: 2.64, 95% CI: 1.06-6.53, \( P = 0.04 \)) and BMT group (OR: 6.53, 95% CI: 2.35-18.19, \( P = 0.0003 \)) compared with the controls. No significant difference in the incidence of TPMT polymorphisms was found in the hepatotoxicity group (OR: 1.51, 95% CI: 0.47-4.82, \( P = 0.49 \)) and pancreatitis group (OR: 0.46, 95% CI: 0.06-3.47, \( P = 0.45 \)) compared with the controls.

**DISCUSSION**

This review evaluated 17 published studies that have studied the association between TPMT gene polymorphisms and the development of ADRs in thiopurine-treated IBD patients. Nine studies among adult IBD patients were included, while the random effects model was used for the meta-analysis. The results of the present meta-analysis suggested that IBD patients with TPMT polymorphisms are more likely to experience ADRs, in particular BMT, but not hepatotoxicity and pancreatitis. Notably, the result
remained significant after the sensitivity analysis.

The association of TPMT polymorphisms with thiopurine toxicity suggested by previous studies is confirmed in this meta-analysis. The study of Ansari et al was the largest prospective study to use full-dose AZA (2 mg/kg) without dose adjustment in IBD patients. They have found that heterozygous TPMT genotype strongly predicted ADRs (79% heterozygous vs 35% wild-type TPMT, \( P < 0.001 \)), especially for gastric intolerance and BMT. Another study has shown that heterozygous TPMT genotypes were significantly associated with IBD patients experiencing nausea and vomiting. Although several studies have demonstrated that there was no association between thiopurine-related ADRs and TPMT polymorphisms, the retrospective nature of most of these studies may not have provided a true measure of ADRs. The OR for mutations of the TPMT gene in thiopurine-treated IBD patients suffering from overall ADRs was 2.93.

A higher frequency of TPMT mutation was seen in thiopurine-treated IBD patients with BMT than in those without BMT. This was corroborated in the sensitivity analysis. TPMT polymorphisms results in greater conversion of 6-MP to 6-thioguanine nucleotides (6-TGNs) and methylthioinosine monophosphate (meTIMP) via the xanthine guanine phosphoribosyltransferase pathway. 6-TGNs and meTIMP are thought to be associated with BMT. The study by Hindorf et al has suggested that BMT might be dose-related; 67% of the 27 patients with ADRs tolerated long-term treatment with a lower dose (median 1.32 mg/kg per day AZA), and low-dose AZA/6-MP was as effective as the standard dose for remission induction and maintenance of remission in patients with UC and CD, but this was not confirmed in the sensitivity analysis of studies that prescribed AZA/6-MP as effective as the standard dose for remission induction and maintenance of remission in patients with UC and CD, but this was not confirmed in the sensitivity analysis of studies that prescribed AZA/6-MP as effective as the standard dose for remission induction and maintenance of remission in patients with UC and CD. This was corroborated in the sensitivity analysis of studies that prescribe AZA/6-MP as effective as the standard dose for remission induction and maintenance of remission in patients with UC and CD.

Previous studies have found an association between heterozygotes for the TPMT*3A allele and hepatotoxicity in acute lymphocytic leukemia patients who received a standard dose of 6-MP/6-TG. However, it was not shown in this meta-analysis. The results of the present study showed no increase in the incidence of TPMT polymorphisms in thiopurine-treated IBD patients with hepatotoxicity compared with those without hepatotoxicity. This was confirmed in the sensitivity analysis. TPMT polymorphisms are seldom found in patients exhibiting thiopurine-related hepatotoxicity, and thiopurine-induced hepatotoxicity cannot be generally attributed to it. It has been suggested that elevated concentrations of 6-methylmercaptopurine (6-MMP) are associated with thiopurine-induced hepatotoxicity, and elevated concentrations of 6-MMP could be due to high TPMT activity but not TPMT polymorphisms.

No significant difference was found in the incidence of TPMT polymorphisms between the thiopurine-treated IBD patients with and without pancreatitis. The results of the sensitivity analysis also showed no significant difference. Thiopurine-induced pancreatitis is dose-independent and seems to be independent of TPMT polymorphisms. AZA is a drug that can induce pancreatitis, especially when it is used in the treatment of CD, which might be due to an immune-mediated idiosyncratic drug reaction because of a genetic predisposition.

Recently, Higgins et al have published a meta-analysis of myelosuppression in patients with intermediate TPMT activity compared with wild-type. They have found that individuals with intermediate TPMT activity or one TPMT variant allele had an increased risk of developing thiopurine-induced BMT, compared with individuals with normal activity. The search was not limited to a specific disease or condition. They included a total of 67 studies, but most of them were retrospective cohorts. The genotype and/or phenotype tests were described in 57 studies. As we know, the overall concordance rate between the genetic and phenotypic tests for TPMT was 71.6%. In addition, the cutoff points of TPMT activity have varied in different groups. The phenotype test might also be influenced by blood transfusion during the previous 3 mo. The most important thing is that prospective studies that have evaluated the cost-effectiveness of the phenotype test used in IBD treatment have been rather scarce.

This meta-analysis has several weaknesses, most of which relate to homogeneous definitions of BMT, hepatotoxicity and pancreatitis. Therefore, we had to base our analysis on studies that were vulnerable to bias. Second, all of the included studies were performed in populations of European descent. Further studies are needed in other countries because of ethnic differences in TPMT polymorphisms. Third, the low number of ADRs made statistical precision difficult. Finally, it should be noted that not all of the ADRs could be explained only by TPMT genotyping, but also by other reasons, such as concurrent viral infections, or co-medication (e.g. mesalamine or sulfasalazine), which can interfere with thiopurine metabolism.

In conclusion, this meta-analysis provides strong evidence that TPMT polymorphisms are associated with overall ADRs and BMT in patients taking 6-MP or AZA, and thus may be useful in the management of these patients. The present study also clearly demonstrates that thiopurine-related hepatotoxicity and pancreatitis cannot be explained by TPMT polymorphisms. Although there is no consensus that TPMT genotype should be measured before embarking on therapy with thiopurine in IBD patients, based on our meta-analysis, we believe that TPMT genotyping is warranted before embarking on therapy with thiopurine in IBD patients. This is also suggested by the US Food and Drug Administration recommendations and by one socioclimatic study of IBD patients.

COMMENTS

**Background**

The efficacy of the thiopurines has been well established for the treatment of...
inflammatory bowel disease (IBD). However, they have severe adverse drug reactions (ADRs) such as gastrointestinal disturbances, bone marrow toxicity (BMT), hepatotoxicity and pancreatitis that prevent their use in some patients. The impact of genetic variation of the thiopurine S-methyltransferase (TPMT) gene on its toxicity has been evaluated in several studies, with varying outcomes.

**Research frontiers**

Recent pharmacogenetic advances have led to the development of novel strategies to optimize and individualize therapy with azathioprine (AZA) and 6-mercaptopurine (6-MP). The strategy of screening the TPMT gene mutation might maximize efficacy while minimizing toxicity.

**Innovations and breakthroughs**

The results of the previous studies on TPMT polymorphisms and thiopurine toxicity have been inconsistent. Recent, one meta-analysis has found that individuals with both intermediate and absent TPMT activity had an increased risk of developing thiopurine-induced BMT. However, there is still no prospective study that has evaluated the cost-effectiveness and utility of the TPMT phenotyping test before starting thiopurine medication, while TPMT genotyping is recommended by one socioeconomic study in IBD patients. This meta-analysis has shown that IBD patients with TPMT polymorphisms are at risk of increased thiopurine toxicity when taking thiopurine medications.

**Applications**

The meta-analysis provides strong evidence that the TPMT polymorphisms are associated with overall ADRs and BMT in patients taking 6-MP or Aza. Based on the meta-analysis, it is believed that TPMT genotyping is warranted before embarking upon therapy with thiopurine in IBD patients.

**Terminology**

TPMT is a cytosolic enzyme that methylates thiopurine compounds. This gene encodes the enzyme that metabolizes thiopurine drugs via S-adenosyl-L-methionine as the S-methyl donor and S-adenosyl-L-homocysteine as a byproduct. Genetic polymorphisms that affect this enzymatic activity are correlated with variations in sensitivity and toxicity to such drugs within individuals.

**Peer review**

The authors describe a meta-analysis of associations between TPMT genetic polymorphisms and ADRs, including BMT, hepatotoxicity, and pancreatitis. The authors’ attempt at meta-analysis is interesting, considering current contradictory data about the efficacy of TPMT genotyping in predicting AZA/6-MP toxicity. Moreover, their claims are reasonable.

**REFERENCES**

1. Prefontaine E, Sutherland LR, Macdonald JK, Cerou M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009; CD000067
2. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2009; CD000545
3. Hindorf U, Lindqvist M, Peterson C, Söderkvist P, Ström M, Hjortswang H, Pousset A, Almer S. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut 2006; 55: 1423-1431
4. Yates CR, Krynetski EY, Loenmenchen T, Fessing MY, Tai HL, Pui CH, Relling MV, Evans WE. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126: 608-614
5. Winter JW, Gaffney D, Shapiro D, Spooner RJ, Marinaki AM, Sanderson JD, Mills PR. Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2007; 25: 1069-1077
6. Cao Q, Zhu Q, Shang Y, Gao M, Si J. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease. Digestion 2009; 79: 58-63
7. Takatsu N, Matsui T, Murakami Y, Ishihara H, Hisabe T, Nagahama T, Maki S, Beppu T, Takaki Y, Hirai F, Yao K. Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol 2009; 24: 1258-1264
8. Uchiyama K, Nakamura M, Kubota T, Yamane T, Fujise K, Tajiri H. Thiopurine S-methyltransferase and inosine triphosphate pyrophosphohydrolase genes in Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine/6-mercaptopurine treatment. J Gastroenterol 2009; 44: 197-203
9. Ban H, Andoh A, Tanaka A, Tsujiikawa T, Sasaki M, Saito Y, Fujiyama Y. Analysis of thiopurine S-methyltransferase genotypes in Japanese patients with inflammatory bowel disease. Intern Med 2008; 47: 1645-1648
10. Geary RB, Barclay ML, Burt MJ, Colletta JA, Chapman BA, Roberts RL, Kennedy MA. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurines in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 395-400
11. Regueroi M, Mardini H. Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease. J Clin Gastroenterol 2002; 35: 240-244
12. Evans WE, Hon YY, Bongmaars L, Coutre S, Holdsworth M, Janco R, Kalwinsky D, Keller F, Khatib Z, Margolin J, Murray J, Quinn J, Ravindranath Y, Ritkey C, Roberts W, Rogers ZR, Schiff D, Steuber C, Tucci F, Kornegay N, Krynetski EY, Relling MV. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001; 19: 2290-2301
13. Naughton MA, Battalgia E, O'Brien S, Walport MJ, Botto M. Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology (Oxford) 1999; 38: 640-644
14. Ansari A, Arenas M, Greenfield SM, Morris D, Lindsay J, Gilshenan K, Smith M, Lewis C, Marinaki A, Duley J, Sanderson J. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008; 26: 973-983
15. Hawwa AF, Millership JS, Collier PS, Vandenbroeck K, McCarthy A, Dempsey S, Cairns C, Collins J, Rodgers C, McElney JC. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br J Clin Pharmacol 2008; 66: 517-528
16. Stocco G, Martelossi S, Barabino A, Decorti G, Bartoli F, Montico M, Gotti A, Ventura A. Glutathione-S-transferase genotype or phenotype optimizes initial dosing of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008; 29: 973-983
17. Palmieri O, Latiano A, Bossa F, Vecchi M, D’Incal R, Guagnozzi D, Tonelli F, Cucchiara S, Valvano MR, Latiano T, Andruilli A, Annese V. Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurines’ toxicity and efficacy. Aliment Pharmacol Ther 2007; 26: 737-745
18. Zelinkova Z, Derijks LJ, Skotter PS, Vogels EW, van Kampen AH, Curvers WL, Cohn D, van Deventer SJ, Hommes DW. Inosine triphosphate pyrophosphatase and thiopurine S-methyltransferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 57-64
19. Palmieri O, Latiano A, Bossa F, Vecchi M, D’Incal R, Guagnozzi D, Tonelli F, Cucchiara S, Valvano MR, Latiano T, Andruilli A, Annese V. Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurines’ toxicity and efficacy. Aliment Pharmacol Ther 2007; 26: 44-49
20. Derijks LJ, Gilissen LP, Engels LG, Bos LP, Bus PJ, Lohman JJ, Curvers WL, Van Deventer SJ, Hommes DW, Hooymans PM. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit 2004; 26: 311-318
21. Schwab M, Schäffeler E, Marx C, Fischer C, Lang T, Behrens C, Gregor M, Eichelbaum M, Zanger UM, Kaskas BA. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002; 12: 429-436
Marinaki AM, Ansari A, Duley JA, Arenas M, Sumi S, Lewis CM, Shobowale-Bakre el-M, Escuredo E, Fairbanks LD, Sanderson JD. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004; 14: 181-187

Geary RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 2005; 20: 1149-1157

Kim DU, Kim YH, Kim BJ, Chang DK, Son HJ, Rhee PL, Kim JJ, Rhee JC. The efficacy of low dose azathioprine/6-mercaptopurine in patients with inflammatory bowel disease. Hepatogastroenterology 2009; 56: 1395-1402

Alves S, Prata MJ, Ferreira F, Amorim A. Thiopurine methyltransferase pharmacogenetics: alternative molecular diagnosis and preliminary data from Northern Portugal. Pharmacogenetics 1999; 9: 257-261

Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 904-915

Weersma RK, Peters FT, Oostenbrug LE, van den Berg AP, Homan van der Heide JJ, Jansen PL, van Dullemen HM. Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases. Aliment Pharmacol Ther 2004; 20: 843-850

Higgs JE, Payne K, Roberts C, Newman WG. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics 2010; 11: 177-188

Serpe L, Calvo PL, Muntoni E, D’Antico S, Giacone M, Avagnina A, Baldi M, Barbera C, Curti F, Pera A, Eandi M, Zara GP, CanaparO R. Thiopurine S-methyltransferase pharmacogenetics in a large-scale healthy Italian-Caucasian population: differences in enzyme activity. Pharmacogenomics 2009; 10: 1753-1765

Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, Soule JC, Modigliani R, Touze Y, Catala P, Libersa C, BrolY F. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-1030

Lowry PW, Franklin CL, Weaver AL, Szumlanski CL, Mays DC, Loftus EV, Tremaine WJ, Lipsky JJ, Weinshilboum RM, Sandborn WJ. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001; 49: 656-664

Pierik M, Rutgeerts P, Vliegertuck R, Vermeire S. Pharmacogenetics in inflammatory bowel disease. World J Gastroenterol 2006; 12: 3657-3667

Package insert for azathioprine/6-mercaptopurine. San Diego, CA: Prometheus Laboratories, Inc., 2005

Winter J, Walker A, Shapiro D, Gaffney D, Spooner R, Mills PR. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20: 593-599

S- Editor Tian L  L- Editor Kerr C  E- Editor Lin YP